caa a22 4500 397591071 CHVBK 20180308164938.0 cr unu---uuuuu 161202e199602 xx s 000 0 eng 10.1093/jac/37.2.209 doi (NATIONALLICENCE)oxford-10.1093/jac/37.2.209 Wood Martin J. Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham B9 5ST, UK The comparative efficacy and safety of teicoplanin and vancomycin [Elektronische Daten] [Martin J. Wood] Glycopeptide antibiotics, such as teicoplanin and vancomycin, are active against staphylococci (including methicillin resistant strains), streptococci, enterococci and Clostridium spp. Vancomycin and teicoplanin are both widely used in the treatment of infections caused by Gram-positive organisms. Vancomycin can, however, provoke a number of side-effects, and serum concentrations should be monitored during treatment. Teicoplanin has a longer half-life than vancomycin, it can be given as an intravenous bolus or by intramuscular injection, and nephrotoxicity and ototoxicity are relatively uncommon. Treatment with teicoplanin might, therefore, offer advantages over treatment with vancomycin—provided that similar clinical efficacy can be shown. At least 11 clinical trials comparing the efficacy and safety of teicoplanin and vancomycin have been carried out worldwide. Meta-analysis of the combined results from these studies indicates that more than three-quarters of the patients in each of the treatment groups had a clinical response to therapy. Meta-analysis of the numbers of adverse events occurring in each treatment group shows significantly fewer reports of adverse events in patients receiving teicoplanin (13.9%) than in those receiving vancomycin (21.9%). Direct comparisons are difficult because of inherent differences between studies, but available data suggest that teicoplanin is as effective as vancomycin and that its superior tolerability together with advantages such as once-daily bolus administration, intramuscular use and lack of requirement for routine serum monitoring, give it considerable potential for use in clinical practice. © 1996 The British Society for Antimicrobial Chemotherapy Review nationallicence Journal of Antimicrobial Chemotherapy Oxford University Press 37/2(1996-02), 209-222 0305-7453 37:2<209 1996 37 jac https://doi.org/10.1093/jac/37.2.209 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.2.209 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Wood Martin J. Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham B9 5ST, UK NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/2(1996-02), 209-222 0305-7453 37:2<209 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford